Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | TCF4 | P15884 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826368 | 0.90 | KDR (0.43) | KDRMAPKAPK2 | |
| SCHEMBL23999478 | 0.85 | KDR (0.40) | KDRTNFTCF4CTNNB1CCNB2 | |
| SCHEMBL30180305 | 0.85 | KDR (0.40) | KDRTNFTCF4CTNNB1CCNB2 | |
| SCHEMBL25826462 | 0.83 | KDR (0.37) | KDRTCF4CTNNB1AURKATLR9 | |
| SCHEMBL26310209 | 0.81 | KDR (0.33) | KDRTNFMAPKAPK2AURKATLR9 | |
| SCHEMBL30180637 | 0.79 | KDR (0.45) | KDRTCF4CTNNB1MAPKAPK2AURKA | |
| SCHEMBL23999674 | 0.79 | KDR (0.45) | KDRTCF4CTNNB1MAPKAPK2AURKA | |
| SCHEMBL30180266 | 0.77 | KDR (0.39) | KDRTNFTCF4CTNNB1AURKA | |
| SCHEMBL23999443 | 0.77 | KDR (0.39) | KDRTNFTCF4CTNNB1AURKA | |
| SCHEMBL23999658 | 0.76 | KDR (0.41) | KDRTCF4CTNNB1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3271/4885TNF 4414/4885TCF4 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.